Michael E. Thase, MD
Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania
Original Research
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
August 11, 2025
Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
Academic Highlights
Patient Functioning, Life Engagement, and Treatment Goals in Major Depressive Disorder
September 7, 2022
Patients with MDD often report lack of motivation and energy and a feeling of disengagement from their own lives. Here, experts discuss treatment strategies that may be favorable for...
Insights
Patient Functioning and Life Engagement: Treatment Goals in Schizophrenia
August 17, 2022
Many people with schizophrenia feel isolated and disengaged from their own lives even when symptoms are under control. Here, experts discuss assessment of life engagement and treatment strategies that...
Academic Highlights
Patient Functioning, Life Engagement, and Treatment Goals in Schizophrenia
August 17, 2022
Many people with schizophrenia feel isolated and disengaged from their own lives even when symptoms are under control. Here, experts discuss assessment of life engagement and treatment strategies that...
Academic Highlights
Patient Functioning and Life Engagement: Unmet Needs in MDD and Schizophrenia
August 3, 2022
Besides achieving symptom relief and improved functioning, many patients with serious mental illness wish to connect more with others and feel engaged with their lives. Five experts discuss life...
Original Research
Adjunctive Pimavanserin and Sleep/Wakefulness in MDD
December 1, 2020
Adjunctive pimavanserin can reduce depressive symptoms and improve function in patients with major depression and inadequate antidepressant response. This analysis evaluated the effects of adjunctive pimavanserin on sleep/wakefulness disturbances.
